• Share your contact details to receive free updated sample copy/pages of the recently published edition of Benign Prostatic Hyperplasia Treatment Market Report 2023. (cognitivemarketresearch.com)
  • Global Benign Prostatic Hyperplasia Treatment's market size was $6.27 Billion in 2022 whereas it will rise to $8.79 Billion with the Compound Average Growth Rate of 4.94% (2023 to 2030). (cognitivemarketresearch.com)
  • The global nasal drug delivery technology market size is expected to grow from $72.16 billion in 2022 to $77.42 billion in 2023 at a compound annual growth rate (CAGR) of 7.29% . (thebusinessresearchcompany.com)
  • IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation ("Nymox") (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella. (bigcountryhomepage.com)
  • June 5, 2023) - Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced market availability of its newest electrosurgical generator for use in the treatment of bladder cancer and enlarged prostate. (olympusamerica.com)
  • The global Benign Prostatic Hyperplasia (BPH) treatment market size was USD 11.50 Billion in 2022 and is expected to register a rapid revenue CAGR of 5.3% during the forecast period. (emergenresearch.com)
  • Global Benign Prostatic Hyperplasia Treatment Market size was $6.27 Billion in 2022! (cognitivemarketresearch.com)
  • The market further generated revenue of ~USD 7.0 billion in the year 2022. (marylanddailygazette.com)
  • End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 The global cardiopulmonary oxygenator market was valued at US$742.12 million in 2022. (marketresearch.com)
  • Intramuscular, Subcutaneously, and Epidural), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 The global home infusion therapy market in 2022 was valued at US$23.55 billion. (marketresearch.com)
  • CHICAGO, Dec. 14, 2020 /PRNewswire/ -- The global benign prostatic hyperplasia (BPH) devices market is expected to grow at a CAGR of over 22% during the period 2019-2025. (epicos.com)
  • Analysis of market trends in the region, with market data considering 2019 as the base year, 2020 as the estimate year and forecast for 2027 with projection of CAGR from 2020 to 2027. (globalindustryreports.com)
  • The Endoscopy Devices segment is anticipated to have the largest share of the market in 2020 and is poised to dominate the market during the forecast period 2021-2026. (industryarc.com)
  • The Kidney Diseases segment accounted for the largest share of the market in 2020. (industryarc.com)
  • It is a system developed for men living with median lobe obstruction and benign prostatic hyperplasia (BPH). (marylanddailygazette.com)
  • Surgical Treatment Options for Benign Prostatic Obstruction This article provides a comprehensive review of the available surgical treatment options for benign prostatic obstruction. (medscape.com)
  • Minimally Invasive Surgery for Benign Prostatic Obstruction Learn more about the available minimally invasive techniques for the surgical treatment of benign prostatic obstruction. (medscape.com)
  • The data support a long-term biological mechanism of action whereby compression-induced localized tissue remodeling is initiated by the UroLift System implant placement and leads to a widened prostatic urethra. (urolift.com)
  • The UroLift implant pulls the enlarged prostate toward the capsule, thereby mechanically creating an immediate, visible deobstruction in the prostatic urethra. (urolift.com)
  • That's why MarketResearch.com offers a wide range of pharmaceutical reports, providing critical insights into market trends, industry challenges, and emerging opportunities. (marketresearch.com)
  • Many clinics and urology centers have laser equipment that is used to treat the patient population, which boosts the BPH devices market in the region. (epicos.com)
  • The clinical trials carried out in partnership with the main French urology centers, including Val de Grâce Hospital, Saint-Charles de Montpellier Hospital and Besançon University Hospital, concluded that the prescription drug was effective in the treatment of Benign Prostatic Hyperplasia (BPH) . (pierre-fabre.com)
  • The Urology Devices Market size is estimated to reach $45.2 billion by 2026, growing at a CAGR of 4.7% during the forecast period 2021-2026 . (industryarc.com)
  • August 20, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of clinical data for the UroLift ® System in the peer-reviewed journal Prostate Cancer and Prostatic Disease . (urolift.com)
  • The new cases of prostate ailments and minimally surgical procedures as well as potency and efficacy of the new drugs will drive growth of the benign prostatic hyperplasia treatment market. (medgadget.com)
  • The growth of the global benign prostatic hyperplasia (BPH) prostate treatment market can majorly be attributed to skyrocketing research and development process to find new systems and drugs to cure the disease. (marylanddailygazette.com)
  • Efficacy and Safety of Dutasteride and Finasteride in BPH Are these two drugs safe and effective options for the treatment of benign prostatic hyperplasia? (medscape.com)
  • Ascella presumably thought that Nymox would submit to or collapse under these coordinated assaults on its business, allowing Ascella to reap the years of Nymox's efforts to take its pipeline drugs including NYMOZARFEX™ to market. (bigcountryhomepage.com)
  • Nymox has not been deterred from its core business mission of bringing life changing drugs to market and looks forward to continued success notwithstanding the bad acts of Ascella. (bigcountryhomepage.com)
  • Cialis generics are analogues of branded drugs that are marketed by the US-based pharmaceutical company Eli Lilly. (truecoverage.com)
  • In the US, under a license from Astellas, BIPI has been marketing the product since 1997 under the brand name FLOMAX. (astellas.com)
  • The mono drug therapy segment is expected to register steadily fast revenue growth rate in the global BPH treatment market during the forecast period. (emergenresearch.com)
  • The report provides market estimates for base year 2019 and a yearly forecast to 2027 in terms of revenue (USD Billion) unless stated otherwise. (globalindustryreports.com)
  • Market for each segment has been provided on a global and regional for the above-mentioned forecast period. (globalindustryreports.com)
  • The report analyzes and forecast the market size in terms of volume and value. (globalindustryreports.com)
  • The global benign prostatic hyperplasia (BPH) devices market is expected to observe an absolute growth of over 242% during the forecast period. (tealfeed.com)
  • Therefore, the higher demand for treatment is expected to flourish the market growth over the forecast period. (marylanddailygazette.com)
  • Hence, this factor is expected to be the major hindrance to the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market during the forecast period. (marylanddailygazette.com)
  • The global increase in disposable income and R&D in Urological Devices by key market players is anticipated to drive the market during the forecast period. (industryarc.com)
  • Additionally, the market is expected to register robust growth in key regions like North America. (medgadget.com)
  • 2. North America and Europe are expected to grow faster than the global market CAGR, due to high penetration minimally invasive surgical procedures for treating BPH. (epicos.com)
  • However, side effects in BPH treatment is a major factor, which could restrain market revenue growth. (emergenresearch.com)
  • Sometimes BPH surgery shows different side effects, such as urinary tract infection, heavy bleeding, difficulty holding urine, etc., which could also restrain market revenue growth. (emergenresearch.com)
  • Urology Devices are used for the diagnostics and treatment of diseases affecting the urinary systems and the male reproductive system such as Benign Prostatic Hyperplasia (BPH), Pelvic Organ Prolapse, and Prostate Cancer. (industryarc.com)
  • However, stringent government regulations imposed in the Urology Devices Industry are anticipated to challenge market growth. (industryarc.com)
  • The Urology Devices Market based on Disease can be further segmented Kidney Disease, Prostate Cancer, Urological Cancer, Pelvic Organ Prolapse, Benign Prostatic Hyperplasia, and Others. (industryarc.com)
  • The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. (urolift.com)
  • Earlier, the disease was mostly linked with age, however, a particular age group of gender, and other factors like low BPH, numerous supporting government grants for research will drive new opportunities for growth in the benign prostatic hyperplasia treatment market. (medgadget.com)
  • The surrounding campaigns like national prostate health month, and rising awareness of the disease in the region are expected to create new opportunities for players in the benign prostatic hyperplasia treatment market. (medgadget.com)
  • The widespread nature of this disease, and growth in related illnesses such as prostate cancers , obesity, stomach related ailments will drive robust growth for the BPH market in the near future. (medgadget.com)
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita. (clarivate.com)
  • Major key factors propelling the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market worldwide are higher demand for the treatment for BPH surgical treatment owing to the severity of the disease. (marylanddailygazette.com)
  • 5-Alpha Reductase Inhibitors in Prostatic Disease and Beyond 5-alpha reductase inhibitors are effective in the treatment of benign prostatic hyperplasia, but these medications could have potential benefits for other conditions as well. (medscape.com)
  • Specifically, the new research describes a new application of terazosin (TZ) - a drug commonly used to treat benign prostatic hyperplasia and hypertension - to fight the progression of Parkinson's disease. (idibell.cat)
  • The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. (jptcp.com)
  • Due to rising prostate issues including growth of major issues like prostate cancer, the market will likely reach US 12 billion in valuation by 2027. (medgadget.com)
  • The global nasal drug delivery technology market size is expected to reach $101.49 billion in 2027 at a CAGR of 7% . (thebusinessresearchcompany.com)
  • 6. Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. (jptcp.com)
  • In addition to cutting down on junk food, maintaining your weight and quitting smoking may become game-changing in coping with prostatic gland enlargement. (almagia.com)
  • This portable gadget can serve you both at home and in a hospital, alleviating your unpleasant sensations caused by prostatic gland enlargement. (almagia.com)
  • Megestrol is also sometimes used to treat malnutrition in patients with cancer, prostatic hypertrophy (enlargement of a male reproductive gland called the prostate), endometriosis (condition in which the type of tissue that lines the uterus grows in other areas of the body), and endometrial hyperplasia (overgrowth of the lining of the uterus). (medlineplus.gov)
  • This study explains the mechanism of action through which the UroLift System provides long-term durability and sustained results for patients with benign prostatic hyperplasia (BPH), also referred to as enlarged prostate. (urolift.com)
  • Taken together, the biocompatibility and stability of the UroLift System implants appear to be superior to prostatic stents, with studies of prostatic stents showing that up to 47% of men require removal of their implants due to complications associated with migrations and encrustations. (urolift.com)
  • The UroLift System is the first mechanical prostatic implant to demonstrate safe and effective treatment of BPH without common issues associated with prior stents. (urolift.com)
  • More than 250,000 men have been treated with the UroLift System in select markets worldwide. (urolift.com)
  • For instance, a system, Rezum System, launched by NxThera, Inc, is observed to be more effective and quicker in results compared to other pharmaceutical agents for benign prostatic hyperplasia. (marylanddailygazette.com)
  • As a horizon scanning stage, the Dental and Pharmaceutical Benefits Agency (TLV) is currently conducting a thematic survey regarding medical technologies to be used as an alternative to transurethral prostate resection in benign prostatic hyperplasia. (mtrconsult.com)
  • Since the early 1980s, Pierre Fabre's pharmaceutical business has been a key player in the treatment of Benign Prostatic Hyperplasia (BPH) . (pierre-fabre.com)
  • Major pharmaceutical companies operating in the nasal drug delivery technology market are involved in developing new and improved products to provide their customers with new methods of drug administration to sustain their position in the market. (thebusinessresearchcompany.com)
  • Finasteride was originally distributed by pharmaceutical giant Merck & Co. in a 5 mg dose under the brand name Proscar for treatment of Benign Prostatic Hyperplasia (BPH). (regrowhair.com)
  • The pharmaceutical market is brimming with alpha-blockers that may be must-haves in your benign prostatic hyperplasia treatment. (almagia.com)
  • According to a new TMR report, the benign prostatic hyperplasia treatment market is expected to grow at a robust 6% CAGR during 2019 to 2027. (medgadget.com)
  • The report includes the analysis of the regional as well as global market trends, key players, market segments, application areas, and growth strategies. (globalindustryreports.com)
  • We received the below report on the U.S. market from you. (fortunebusinessinsights.com)
  • Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Urological Devices Report. (industryarc.com)
  • Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. (strategyr.com)
  • After several years research and an adjustment in the dose of finasteride from 5mg to 1mg, this new use for finastride was marketed under the name Propecia as a treatment for male pattern baldness. (homehealth-uk.com)
  • The Dialysis Equipment market is projected to grow the fastest at a CAGR of 5.1% owing to the global increase in kidney disorders. (industryarc.com)
  • Horizon's investment enables us to continue our efforts to bring our treatment to market, as well as aid us in developing additional solutions to treat other common urological conditions. (prnewswire.com)
  • In 1993, the Pierre Fabre Group strongly believed there was a gap in the market and became the first company to market a product to treat iron deficiency and to prevent iron deficiency in pregnant women. (pierre-fabre.com)
  • Finastride was first used under the brand name Proscar to treat benign prostatic hyperplasia (BHP), also known as an enlarged prostate. (homehealth-uk.com)
  • The increasing geriatric population is another driving factor for the benign prostatic hyperplasia treatment market. (cognitivemarketresearch.com)
  • however, the growing number of the elderly men population is a primary factor responsible for influencing the growth of the BPH devices market. (tealfeed.com)
  • Transparency Market Research is a global market intelligence company providing global business information reports and services. (medgadget.com)
  • On the basis of treatment type, the global BPH treatment market is segmented into combination drug therapy and mono-drug therapy. (emergenresearch.com)
  • Recent Trend and Developments: The major players operating in the global market have adopted key strategies such as product launch and acquisition to strengthen their market outreach and sustain the stiff competition in the market. (globalindustryreports.com)
  • Market Study by Global Industry Analysts, Inc. (strategyr.com)
  • This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. (mtrconsult.com)
  • Prescription drug market in the United States teenagers, the side that the doctors do not inform the patients about. (xamuel.com)
  • Recently, Information Resources Inc. (IRI) reported saw palmetto was the fourth best-selling herb in the food, drug and mass market channel in 2008, increasing 3.2 percent from 2007 to a total of $17.5 million in 2008 sales. (naturalproductsinsider.com)
  • The increasing incidences of chronic diseases are expected to propel the growth of the nasal drug delivery technology market going forward. (thebusinessresearchcompany.com)
  • Therefore, the increasing incidences of chronic diseases are driving the growth of the market for nasal drug delivery systems. (thebusinessresearchcompany.com)
  • Product innovations are a key trend gaining popularity in the nasal drug delivery technology market. (thebusinessresearchcompany.com)
  • During last few years efforts have been taken to license out patents and the drug for benign prostatic hyperplasia has already been launched into Indian market. (iicb.res.in)
  • 5. Vendors need to strategically focus on the development and commercial launches of advanced BPH treatment devices that can be used in in-office settings to penetrate and tap the huge growth potential prevailing in the market. (epicos.com)
  • Though the high cost of BPH devices can affect the market adversely, the presence of reimbursement coverage for both invasive and MI treatment options will have a positive impact on the growth of the market. (epicos.com)
  • To provide detailed information regarding drivers, restraints, opportunities and challenges are influencing the growth in the respective market. (globalindustryreports.com)
  • Dihydrotestosterone (DHT), a metabolite of testosterone, is a critical mediator of prostatic growth. (wikipedia.org)
  • It covers a detailed overview of several market growth enablers, restraints, and trends. (tealfeed.com)
  • Therefore, the market is growing at significant growth, and the region is dominating the market and expected to dominate in the upcoming years. (tealfeed.com)
  • On the other hand, the market growth can also be attributed to the growing number of major key players developing methods to provide treatment for the patient. (marylanddailygazette.com)
  • And disruption abroad is actually a good thing for the U.S. markets, since all that money from outside the U.S. needs a place to go for growth and safety. (investorplace.com)
  • This published study is unique in its amalgamation of three different facets of research by including pre-clinical canine tissue, human tissue, and post-market surveillance data. (urolift.com)
  • The researchers discuss this "prostate lift" is a fundamentally distinct mode of action compared with not only prostatic stents, but also thermal ablation techniques that induce tissue damage and may result in extended periods of edema, retention/catheterization, and higher risks of urinary infections and ejaculatory dysfunction. (urolift.com)
  • 11. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. (jptcp.com)
  • When this occurs, most men are then only left with a variation of a cystoscopic intervention designed to unobstruct the prostatic tissue. (medscape.com)
  • The study offers both the demand and supply aspects of the market. (tealfeed.com)
  • That said, when price does increase and demand either stays the same or risessuch as in years of struggling harvestthe market is ripe for fraud. (naturalproductsinsider.com)
  • The study adopts a systematic approach to review the literature on treatment response in patients with benign prostatic hyperplasia and a notably affected middle lobe. (jptcp.com)
  • Botanical extract giant Naturex-DBS has launched a USDA NOP certified organic cranberry powder to the US market, stating it is a logical extension of its cranberry powders range targeting urinary tract health. (nutraingredients-usa.com)
  • Discusses trends within the market and provides a future outlook. (globalindustryreports.com)
  • We also cover disruptive trends, such as gene editing, precision medicine, and artificial intelligence, ensuring our clients stay ahead of market changes. (marketresearch.com)
  • You are going to receive information on the most current news of the market, in addition to the development, the state and prospects of the market. (computerwise.com)
  • Based on Product Type, the Urological Devices Market is segmented into Dialysis Equipment, Urinary Stone Treatment Devices, Endoscopy Devices, Benign Prostatic Hyperplasia Treatment Devices, Urodynamic Systems, Ultrasound & Other Scanners, and Others. (industryarc.com)
  • Headquartered in San Jose, California , Corinth MedTech develops, manufactures and markets urological device solutions that address unmet needs in an innovative, cost-effective manner. (prnewswire.com)
  • It profiles and examines leading companies and other prominent companies operating in the market. (tealfeed.com)
  • 2. Sandoval E, Fonseca J, Bautista J, Mora C. Benign prostatic hyperplasia: Review article. (jptcp.com)